vs
Side-by-side financial comparison of JBT Marel Corp (JBTM) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
JBT Marel Corp is the larger business by last-quarter revenue ($1.0B vs $699.9M, roughly 1.4× QuidelOrtho Corp). JBT Marel Corp runs the higher net margin — 5.3% vs -104.7%, a 110.0% gap on every dollar of revenue. On growth, JBT Marel Corp posted the faster year-over-year revenue change (115.6% vs -3.7%). JBT Marel Corp produced more free cash flow last quarter ($83.5M vs $-94.7M). Over the past eight quarters, JBT Marel Corp's revenue compounded faster (60.3% CAGR vs -2.9%).
JBT Marel Corporation, formerly known as JBT Corporation, or John Bean Technologies Corporation, is a food processing machinery and automated vehicle company. The company was incorporated in 2008 when FMC Technologies divested its non-energy businesses. The company is based in Chicago, Illinois and traces its history back to a company founded in 1884 by John Bean, an orchardist in Los Gatos, California.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
JBTM vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $699.9M |
| Net Profit | $53.1M | $-733.0M |
| Gross Margin | 34.5% | — |
| Operating Margin | 7.2% | -100.7% |
| Net Margin | 5.3% | -104.7% |
| Revenue YoY | 115.6% | -3.7% |
| Net Profit YoY | 858.6% | -3583.4% |
| EPS (diluted) | $1.04 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | $699.9M | ||
| Q2 25 | $934.8M | $613.9M | ||
| Q1 25 | $854.1M | $692.8M | ||
| Q4 24 | $467.6M | $707.8M | ||
| Q3 24 | $453.8M | $727.1M | ||
| Q2 24 | $402.3M | $637.0M | ||
| Q1 24 | $392.3M | $711.0M |
| Q4 25 | $53.1M | — | ||
| Q3 25 | $66.0M | $-733.0M | ||
| Q2 25 | $3.4M | $-255.4M | ||
| Q1 25 | $-173.0M | $-12.7M | ||
| Q4 24 | $-7.0M | $-178.4M | ||
| Q3 24 | $38.9M | $-19.9M | ||
| Q2 24 | $30.7M | $-147.7M | ||
| Q1 24 | $22.8M | $-1.7B |
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 34.2% | — | ||
| Q4 24 | 38.4% | — | ||
| Q3 24 | 36.1% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 35.8% | — |
| Q4 25 | 7.2% | — | ||
| Q3 25 | 10.2% | -100.7% | ||
| Q2 25 | 5.2% | -29.4% | ||
| Q1 25 | -3.9% | 4.7% | ||
| Q4 24 | 3.4% | -14.2% | ||
| Q3 24 | 10.3% | 2.1% | ||
| Q2 24 | 6.7% | -18.4% | ||
| Q1 24 | 7.4% | -247.3% |
| Q4 25 | 5.3% | — | ||
| Q3 25 | 6.6% | -104.7% | ||
| Q2 25 | 0.4% | -41.6% | ||
| Q1 25 | -20.3% | -1.8% | ||
| Q4 24 | -1.5% | -25.2% | ||
| Q3 24 | 8.6% | -2.7% | ||
| Q2 24 | 7.6% | -23.2% | ||
| Q1 24 | 5.8% | -239.9% |
| Q4 25 | $1.04 | — | ||
| Q3 25 | $1.26 | $-10.78 | ||
| Q2 25 | $0.07 | $-3.77 | ||
| Q1 25 | $-3.35 | $-0.19 | ||
| Q4 24 | $-0.22 | $-2.54 | ||
| Q3 24 | $1.21 | $-0.30 | ||
| Q2 24 | $0.95 | $-2.20 | ||
| Q1 24 | $0.71 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $98.1M |
| Total DebtLower is stronger | $1.5B | $2.5B |
| Stockholders' EquityBook value | $4.5B | $2.0B |
| Total Assets | $8.2B | $5.7B |
| Debt / EquityLower = less leverage | 0.33× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | $1.2B | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | $2.5B | ||
| Q2 25 | $1.5B | $2.1B | ||
| Q1 25 | $2.0B | $2.1B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $648.3M | $2.2B | ||
| Q2 24 | $647.7M | $2.2B | ||
| Q1 24 | $647.0M | $2.2B |
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.4B | $2.0B | ||
| Q2 25 | $4.4B | $2.8B | ||
| Q1 25 | $4.1B | $3.0B | ||
| Q4 24 | $1.5B | $3.0B | ||
| Q3 24 | $1.6B | $3.2B | ||
| Q2 24 | $1.5B | $3.2B | ||
| Q1 24 | $1.5B | $3.3B |
| Q4 25 | $8.2B | — | ||
| Q3 25 | $8.2B | $5.7B | ||
| Q2 25 | $8.3B | $6.4B | ||
| Q1 25 | $8.0B | $6.5B | ||
| Q4 24 | $3.4B | $6.4B | ||
| Q3 24 | $2.8B | $6.8B | ||
| Q2 24 | $2.7B | $6.7B | ||
| Q1 24 | $2.7B | $6.7B |
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.34× | 1.23× | ||
| Q2 25 | 0.35× | 0.74× | ||
| Q1 25 | 0.48× | 0.70× | ||
| Q4 24 | 0.81× | 0.72× | ||
| Q3 24 | 0.41× | 0.68× | ||
| Q2 24 | 0.43× | 0.70× | ||
| Q1 24 | 0.43× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $117.4M | $-45.5M |
| Free Cash FlowOCF − Capex | $83.5M | $-94.7M |
| FCF MarginFCF / Revenue | 8.3% | -13.5% |
| Capex IntensityCapex / Revenue | 3.4% | 7.0% |
| Cash ConversionOCF / Net Profit | 2.21× | — |
| TTM Free Cash FlowTrailing 4 quarters | $238.1M | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $117.4M | — | ||
| Q3 25 | $87.7M | $-45.5M | ||
| Q2 25 | $102.2M | $-46.8M | ||
| Q1 25 | $34.4M | $65.6M | ||
| Q4 24 | $128.7M | $63.7M | ||
| Q3 24 | $71.9M | $117.9M | ||
| Q2 24 | $21.6M | $-97.9M | ||
| Q1 24 | $10.4M | $-700.0K |
| Q4 25 | $83.5M | — | ||
| Q3 25 | $56.5M | $-94.7M | ||
| Q2 25 | $83.7M | $-84.3M | ||
| Q1 25 | $14.4M | $9.4M | ||
| Q4 24 | $118.7M | $16.5M | ||
| Q3 24 | $65.0M | $71.4M | ||
| Q2 24 | $11.1M | $-133.2M | ||
| Q1 24 | $-100.0K | $-66.8M |
| Q4 25 | 8.3% | — | ||
| Q3 25 | 5.6% | -13.5% | ||
| Q2 25 | 9.0% | -13.7% | ||
| Q1 25 | 1.7% | 1.4% | ||
| Q4 24 | 25.4% | 2.3% | ||
| Q3 24 | 14.3% | 9.8% | ||
| Q2 24 | 2.8% | -20.9% | ||
| Q1 24 | -0.0% | -9.4% |
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.1% | 7.0% | ||
| Q2 25 | 2.0% | 6.1% | ||
| Q1 25 | 2.3% | 8.1% | ||
| Q4 24 | 2.1% | 6.7% | ||
| Q3 24 | 1.5% | 6.4% | ||
| Q2 24 | 2.6% | 5.5% | ||
| Q1 24 | 2.7% | 9.3% |
| Q4 25 | 2.21× | — | ||
| Q3 25 | 1.33× | — | ||
| Q2 25 | 30.06× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JBTM
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
